Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.03. | AC Immune files $350M mixed securities shelf | 37 | Seeking Alpha | ||
14.03. | AC Immune verringert Verlust - wichtige Daten in der zweiten Jahreshälfte 2024 | 862 | 4investors | Das Schweizer Biotech-Unternehmen AC Immune hat Zahlen für das Jahr 2023 vorgelegt. Mit einem Cash-Bestand von 103 Millionen Schweizer Franken zuzüglich 40 Millionen Schweizer Franken Meilensteinzahlungen... ► Artikel lesen | |
14.03. | AC Immune SA reports results for the quarter ended in December - Earnings Summary | 11 | Reuters | ||
14.03. | AC Immune SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
14.03. | AC Immune SA - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | ||
14.03. | AC Immune GAAP EPS of -$0.64 beats by $0.17, revenue of $14.8M beats by $3.37M | 6 | Seeking Alpha | ||
14.03. | AC Immune SA: AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update | 604 | GlobeNewswire (Europe) | AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial... ► Artikel lesen | |
22.02. | AC Immune SA: AC Immune Announces Upcoming Presentations at AD/PD 2024 | 1.289 | GlobeNewswire (Europe) | AC Immune Announces Upcoming Presentations at AD/PD 2024
Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024)Andrea Pfeifer, Ph.D., CEO to... ► Artikel lesen | |
23.01. | Roche ducks out of AC Immune Alzheimer's antibody alliance | 93 | pharmaphorum | ||
22.01. | AC Immune erhält Rechte an Antikörpern von Genentech zurück | 1.044 | 4investors | Das Schweizer Biotech-Unternehmen AC Immune erhält nach der Beendigung der Kooperation mit Genentech alle weltweiten Rechte an dem Anti-Amyloid-Beta-Antikörper Crenezumab und dem Anti-Tau-Antikörper... ► Artikel lesen | |
22.01. | AC Immune erhält Rechte zurück | 27 | GoingPublic | ||
22.01. | Roche's Genentech returns Alzheimer's assets to AC Immune, cutting 18-year tie to the biotech | 32 | FierceBiotech | ||
22.01. | Roche ends AC Immune partnership for Alzheimer's drugs | 27 | Seeking Alpha | ||
22.01. | AC Immune To Regain Global Rights To Crenezumab And Semorinemab As Deal With Roche Ends | 555 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - Swiss biopharmaceutical company AC Immune SA (ACIU) announced Monday that it will regain all global rights to the anti-amyloid beta antibody crenezumab and the... ► Artikel lesen | |
22.01. | AC Immune SA - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
22.01. | AC Immune SA: AC Immune to Regain Global Rights to Crenezumab and Semorinemab | 519 | GlobeNewswire (Europe) | AC Immune to Regain Global Rights to Crenezumab and Semorinemab
Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered... ► Artikel lesen | |
03.01. | AC Immune SA - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
03.01. | AC Immune issues updates on Phase 2 studies, cash runway | 22 | Seeking Alpha | ||
03.01. | AC Immune SA: AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases | 644 | GlobeNewswire (Europe) | AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2... ► Artikel lesen | |
15.12.23 | AC Immune Alzheimer's drug advanced into Phase 2b testing | 32 | Seeking Alpha |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 1.046 |
BAYER | 847 |
TUI | 788 |
NEL | 785 |
SIEMENS ENERGY | 683 |
RHEINMETALL | 513 |
MERCEDES-BENZ | 500 |
NVIDIA | 478 |
DEUTSCHE BANK | 424 |
NOVAVAX | 381 |
BYD | 374 |
RWE | 364 |
ALLIANZ | 360 |
PLUG POWER | 356 |
K+S | 332 |
VOLKSWAGEN | 329 |
PALANTIR TECHNOLOGIES | 323 |
COMMERZBANK | 308 |
AIXTRON SE | 298 |
TESLA | 282 |
BASF | 281 |
DEUTSCHE LUFTHANSA | 279 |
NORDEX | 257 |
THYSSENKRUPP | 257 |
ALIBABA | 249 |